Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …

CRISPR-based technologies represent a major breakthrough in biomedical science as they
offer a powerful platform for unbiased screening and functional genomics in various fields …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Cancer-associated
fibroblasts (CAFs) are recognized potential therapeutic targets, but poor understanding of …

Pancreatic cancer (PC) has exceptionally high mortality due to ineffective treatment
strategies. Immunotherapy, which mobilizes the immune system to fight against cancer, has …

Simple Summary There is currently no effective treatment for Pancreatic Ductal
Adenocarcinoma (PDAC), and it is still the deadliest cancer, despite great research efforts in …

Krüppel‐like factor 5 (KLF5) is a member of the KLF family. Recent studies have suggested
that KLF5 regulates the expression of a large number of new target genes and participates …

The dynamic composition of the tumor microenvironment (TME) can markedly alter the
response to targeted therapies for colorectal cancer. Cancer-associated fibroblasts (CAF) …

Pancreatic cancer has a notoriously poor prognosis, exhibits persistent drug resistance, and
lacks a cure. Unique features of the pancreatic tumor microenvironment exacerbate …

Genetic and epigenetic alterations play central roles in shaping the immunosuppressive
tumor microenvironment (TME) to evade immune surveillance. The previous study shows …

Rapid advancements have taken place in gene therapy technology. However, effective
methods for treating aging-or age-related chronic diseases, which are often closely related …